A5073012801- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Myasthenia Gravis and Thymoma
- Neuroendocrine Tumor Research Advances
- PI3K/AKT/mTOR signaling in cancer
- Lung Cancer Diagnosis and Treatment
- Pituitary Gland Disorders and Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Occupational and environmental lung diseases
- Tracheal and airway disorders
- Radiomics and Machine Learning in Medical Imaging
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cancer, Stress, Anesthesia, and Immune Response
- Acute Lymphoblastic Leukemia research
- Genetic factors in colorectal cancer
- Ferroptosis and cancer prognosis
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Treatments and Studies
- Pleural and Pulmonary Diseases
- Esophageal Cancer Research and Treatment
- Cancer Treatment and Pharmacology
- Glioma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Cancer, Lipids, and Metabolism
The Maria Sklodowska-Curie National Research Institute of Oncology
2014-2024
Medical University of Warsaw
2024
National Institute of Oncology
2023
Centrum Onkologii
2011-2021
Centrum Medyczne Kształcenia Podyplomowego
2016
Postgraduate School of Molecular Medicine
2016
Abstract Background Primary tracheal tumors are very rare and the literature on this subject is limited. The most common histological type of primary squamous cell carcinoma (SCC), followed by adenoid cystic (ACC). Limited knowledge exists regarding behavior outcomes different types cancers. present study aimed to address gap assessing significance based our own data review literature. Methods We carried out a retrospective analysis 89 patients with treated at Maria Sklodowska‐Curie National...
Radiological and nuclear medicine methods play a fundamental role in the diagnosis staging of patients with lung cancer. Imaging is essential detection, characterisation, follow-up Due to increasing evidence, low-dose chest computed tomography (CT) screening for early detection cancer being introduced clinical routine several countries. Radiomics radiogenomics are emerging fields reliant on artificial intelligence improve personalised risk stratification. Ultrasound- CT-guided interventions...
Abstract Background: NUT carcinoma (NC) is a rare, aggressive tumor with poor prognosis and no standard treatment. NC arises from NUTM1 gene rearrangements, which drive epigenetic dysregulation uncontrolled proliferation via enhanced RNA polymerase II (RNA-pol II) activity. An analysis of our registry (70 patient) revealed limited benefits current systemic therapies. Among patients on first-line (26), progression-free survival was modest: immunotherapy (5.4months-mo-, 95%CI 3.6-7.1),...
(1) Background: There is a difference in the course of lung cancer between women and men. Therefore, there need to evaluate various factors patient population treated daily practice. The purpose this study was analyze clinical, sociodemographic psychological aspects female cancer. To better express results, we compared (2) Methods: Consecutive patients with history treatment admitted outpatient oncology clinic (Department Lung Cancer Chest Tumours, Maria Skłodowska-Curie National Research...
We presented retrospective analysis of up to five polymorphisms in TS, MTHFR and ERCC1 genes as molecular predictive markers for homogeneous Caucasian, non-squamous NSCLC patients treated with pemetrexed platinum front-line chemotherapy. The following DNA isolated from 115 were analyzed: various number 28-bp tandem repeats 5′-UTR region TS gene, single nucleotide polymorphism (SNP) within the second repeat gene (G>C); 6-bp deletion 3′-UTR (1494del6); 677C>T SNP MTHFR; 19007C>T ERCC1....
A better understanding of the molecular pathogenesis thymic epithelial tumours (TETs) could revolutionise their treatment. We evaluated thymomas and carcinomas by next-generation sequencing (NGS) somatic or germline single nucleotide variants (SNVs) in genes commonly mutated solid tumours. In total, 19 34 were analysed for nonsynonymous SNVs 15 targeted NGS (reference genome: hg19/GRCh37). Ten TP53 (G154V, R158P, L194H, R267fs, R273C, R306 *, Q317 *), ERBB2 (V773M), KIT (L576P), KRAS (Q61L)...
The study was conducted in the era when maintenance immunotherapy with durvalumab not available clinical practice after chemoradiotherapy (CRT) unresectable non-small-cell lung cancer (NSCLC). main aim of to check whether presence cardiovascular diseases (CVD) and their pharmacotherapy affects overall survival (OS) such NSCLC patients undergoing sequential CRT. group 196 were analyzed: 101 CVD (51.53%) 95 other reasons qualification for CRT (decreased performance status, older age,...
Background Thymic epithelial tumors constitute a morphologically and clinically diverse group of rare neoplasm the anterior mediastinum. Methods Here, we present an analysis 188 patients diagnosed with primary thymic between 1995 2015. The prognostic value selected clinical morphological factors was assessed in relation to overall survival recurrence‐free survival. Results risk recurrence increased significantly carcinoma diagnosis ( P = 0.0036), co‐occurrence other diseases, weight loss...
The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented prospective trials. We aim to confirm the benefits indicate predictive factors for immunotherapy daily practice. This study a retrospective analysis. median PFS OS were estimated using Kaplan-Meier method. log-rank test used comparisons. Multivariate analyses performed Cox regression A total 260 patients (ECOG 0-1) with (CS III-IV) eligible receive or as second-line treatment. Median three months (95%...
Abstract Objective Primary tracheal tumors are very rare and their management is not definitely established. Due to its rarity, providing patient care in terms of optimal poses a considerable challenge. The purpose this study was investigate treatment outcomes patients with these tumors. Methods We carried out retrospective analysis 89 primary treated at the Maria Sklodowska-Curie National Research Institute Oncology Warsaw, Poland, over sixteen years. assessed demographics, tumor...
In NSCLC, second-line chemotherapy using pemetrexed or docetaxel has limited efficacy and should be dedicated to selected groups of patients. Pemetrexed is an antifolate compound with the ability inhibit enzymes (TS, DHFR GARFT) involved in pyrimidine purine synthesis. The objective this study was evaluate association between polymorphisms TS MHFR genes clinical outcomes NSCLC patients treated monotherapy. DNA isolated from peripheral blood 72 non-squamous pemetrexed. Using PCR RFLP methods,...
Background The implementation of next-generation sequencing (NGS) into daily practice allows for the identification a greater number molecular abnormalities. We aimed to confirm benefits immunotherapy in group patients with KRAS aberrations treated within clinical practice. Methods This study was retrospective analysis (pts) routine National Drug Programme Poland. NGS performed using FusionPlex Comprehensive Thyroid and Lung (CTL) kit (ArcherDx) sequenced MiniSeq (Illumina). analyses were R...
Introduction: Primary germ cell tumours with mediastinal location comprise 1–6% of and 2–5% all occurring in adults. They are identified mostly the 3rd decade life, 90% cases men. The most common symptoms dyspnea, chest pain, cough, fever weight loss. aim present study was analysis our own results treatment primary location, a review literature concerning this subject. Material Methods: Five patients (4 males, 1 female) median age 27.8 years (range 23–30 years) treated period from 1999 to...
Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated efficacy in the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC) prospective clinical trials.This retrospective analysis evaluated outcomes 32 pretreated patients with EGFR T790M mutation who received osimertinib practice at seven centers Poland within Expanded Drug Access Program. was used second line 59% and later lines 41%.Objective response...
Introduction Pembrolizumab combined with chemotherapy has become the standard of care for patients non-small-cell lung cancer (NSCLC) and expression programmed death ligand 1 (PD-L1) in <50% tumour cells (TC). Methods We evaluated efficacy treatment real-world practice, paying attention to predictive factors, a special focus on low level PD-L1 expression. This study is multicenter retrospective analysis stage IV NSCLC. Results A group 339 consecutive was analysed, among them 51% In...
NC represents a rare malignancy with devastating prognosis. It's produced by the rearrangement of NUTM1 gene, affecting people all ages and arising from different localisations, thoracic being most common. Due to its rarity heterogeneity, there is no standard care for evidence comes retrospective series. Ambispect multicentric international study clinical therapeutic characterisation NC. The primary endpoint describe first-line treatment survival in non-curative curative setting. Secondary...
Indications for immunotherapy in patients with non-small-cell lung cancer (NSCLC) are expanding, an increasing number of receiving the perioperative setting or as consolidation radiochemotherapy. Immune checkpoint inhibitor (ICI)-based regimens also being used more and often first-line systemic setting. However, many cases, efficacy is limited, it necessary to determine optimal sequence treatment. There some theoretical rationale repeated use immune inhibitors, but debatable which subgroups...
Pulmonary benign metastasizing leiomyoma (PBML) is a rare condition characterized by the spread of uterine leiomyomas to lungs, typically observed in premenopausal women with history hysterectomy or myomectomy. This report presents unique case postmenopausal woman, aged 65, that emphasizes clinical, radiological, histologic, and immunohistochemical aspects disease. On presentation, patient suffered from severe pain. imaging, sizable lung tumor was found. Histopathological examination...
Cemiplimab in patients with non-small cell lung cancer (NSCLC) PD-L1 (programmed death ligand type 1) expression ≥50% showed a significant improved overall survival (OS) increasing of PD-L1. To our knowledge there exist no similar data published for pembrolizumab regarding the increased OS relation to expression. Therefore, objective study was determine whether improvement reflects levels (≥50%) NSCLC.